Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| 2022 was an exceptional year at Silence, where we delivered impressive clinical data with SLN360, now known as Zerlasiran for high Lp(a) and made important advancements across our broader pipeline of siRNA therapeutics |
| With Zerlasiran which is a wholly-owned program, we reported up to 98% efficacy in the APOLLO study with strong durability after a single dose |
| As I mentioned in the beginning of this call, 2023 is going to be very exciting for us from an execution and growth perspective |
| We are very pleased with the overall enthusiasm for this program and believe we have opportunities to differentiate in the category |
| It's a combination of a well-tolerated safety profile with great efficacy that is long-lasting, facilitating infrequent dosing |
| We made tremendous progress advancing our platform in the clinic in 2022 and expect to build on that positive momentum in 2023 and beyond |
| While we are limited in what we can disclose with our partnered programs, I can tell you, I'm very encouraged by the continued progress across our collaborations and we expect to communicate more updates this year |
| I'm extremely proud of our 2022 performance and overall results |
| We continue to make excellent headway across both our wholly-owned and partnered pipelines |
| The advantage of being where we are is that we can see what our competitors are doing and allow us to take a slightly different route, one that we think will be very attractive and watch this space |
| 2023 is set to be an exciting year for Silence |
| So we're very confident of our commitment to report by year-end |
| We look forward to another year of strong execution in 2023 |
| Last September, we reported encouraging safety and tolerability data from the single-dose portion of the study as a follow-up to positive data from our healthy volunteer study |
| This has a range of potential therapeutic benefits |
| We also continue to progress our second wholly-owned program, SLN124, in the clinic and reported encouraging preliminary safety results in the GEMINI II Phase I thalassemia study |
| Our cooperations continue to advance and we anticipate that we will achieve additional milestones in 2023 which can further extend our cash runway |
| But as Giles mentioned, given that it's mechanistic in this general area, we have seen some very encouraging data preclinically and we continue to evaluate those for the future |
| And we think there's a real opportunity to differentiate in this area |
| By limiting the availability of iron at the bone marrow, we expect SLN124 will be able to control red cell mass and improve disease outcomes |
| That is what is so attractive about the siRNA platform |
| And as we saw in the Phase I study, we're getting substantially higher than that |
| This speaks to how impressive these data were and the growing recognition that Lp(a) is a major cardiovascular risk factor that needs to be addressed |
| I want to start off by saying how pleased we are at the growing recognition of Lp(a) as a key cardiovascular risk factor |
| Just the first is, I'm wondering if you can tell us what you would hope to learn from the MAD portion of the Phase I trial and how, if at all, new learnings could impact the Phase II program and would it impact more so beyond the future potential outcomes trial? And then how -- can you discuss kind of the level of enthusiasm among investigators and patients regarding enrollment in the Phase II trial and just the level of confidence you have in that 4Q '23 timing for enrollment completion? Craig Tooman Let me say the enthusiasm is very strong and we have a lot of conviction about our year-end goal in terms of enrollment |
| Awareness grew substantially in 2022 and we've seen that trend continue into 2023 |
| As a reminder, SLN124 has FDA fast track and orphan drug designation for polycythemia and orphan drug and rare pediatric disease designation for beta-thalassemia |
| Therefore, as our current collaboration programs progress and additional programs are initiated, our revenue is estimated to increase |
| It's now well recognized that the risk of CV events increases at these levels |
| We see substantial potential for our mRNAi GOLD platform across a range of genetic diseases and look forward to communicating more as we move ahead |
| Statement |
|---|
| Polycythemia vera is a disease of unregulated production of red blood cells, leading to increased risk of thrombosis as well as significant quality of life issues |
| I think we're all digesting the incredible negative response to the Esperion Result |
| As such, this risk factor represents a significant unaddressed health policy issue |
| And I appreciate that there may be other factors that would make that look even better |
| I mean the visibility of Lp(a) as an untreated risk factor has increased exponentially |
| Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC |
| And 15% MACE doesn't seem to be enough for investors |
| The small increase in our net loss is due to the increase in R&D as a result of advancing our programs in clinical development |
| So we don't necessarily think that the first product to market is inevitably going to be the most successful |
| The company's net loss for the full year 2022 was £40.5 million versus a net loss of £39.4 million in 2021 |
Please consider a small donation if you think this website provides you with relevant information